Cardinal Health, Inc.
CAH Healthcare Medical Distribution
Cardinal Health, Inc.’s revenue for fiscal 2026 (year ended June 2026) was $254.2 billion, up 14.2% from fiscal 2025. In the quarter to June 2026, revenue grew 5.84%, EPS grew 68.3%, free cash flow grew 10.9% and total debt rose 4.21%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for twenty-five consecutive years.
Follow CAH
Cardinal Health, Inc. (CAH) P/E ratio
As of 16 October 2026, Cardinal Health, Inc. (CAH) trades at a P/E ratio of 35.0×. Over the past ten years it has ranged from 0.0× (March 2023) to 418× (May 2019); the current reading is higher than 85% of that period. That is above the Healthcare sector median of 23.0×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2026 | 32.7× | 26.21% |
| FY2025 | 25.9× | (9.41%) |
| FY2024 | 28.6× | (69.43%) |
| FY2023 | 93.6× | — |
| FY2022 | 0.0× | — |
| FY2021 | 27.3× | — |
| FY2020 | 0.0× | — |
| FY2019 | 10.5× | (83.77%) |
| FY2018 | 64.7× | 237.80% |
| FY2017 | 19.1× | 7.25% |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 32.7× | 1.74% |
| Mar 2026 | 32.2× | 9.40% |
| Dec 2025 | 29.4× | 24.74% |
| Sep 2025 | 23.6× | (9.10%) |
| 42 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| ACH Accendra Health, Inc. compare | n/m |
| FOCL FocalTherics compare | n/m |
| AHG Akso Health Group Sponsored ADR compare | n/m |
| COSM Cosmos Health Inc. compare | n/m |
| HSIC Henry Schein, Inc. compare | 25.0× |
| COR Cencora, Inc. compare | 25.2× |
| MCK McKesson Corporation compare | 26.8× |
| CAH Cardinal Health, Inc. | 35.0× |
| HKPD Cellyan Biotechnology Co., Ltd compare | — |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)
More on CAH
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement